Follow The Filings

KPTI Karyopharm Therapeutics Inc.

Health Care, filed as KARYOPHARM THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 1.5%
  • $12M
  • 1 add 1 exit

In 2026 Q2 David Witzke added to Karyopharm Therapeutics, while Nathan Fischel sold out.

Who owns this now

Largest portfolio weights among holders, up to 1.5% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Add 1.5%
  2. Davidson Kempner Capital Mana... 0.03%

Who owns KPTI

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 1.5%, was 0.88% Add +99.4% 924,487 $9M History
Davidson Kempner Capital Management 0.03% Hold 300,000 $2.9M History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.06% Exit −0.06% 45,800 $255K History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by KPTI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KPTI insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 21 sales to cover taxes and 19 stock grants.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 3.03,5.03,9.01 Filing Doc
8-K 1.01,2.04,3.02,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated about 6 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $146.03M $145.24M $146.07M
Net income -$143.1M -$76.42M -$196.04M
Net margin * -98.0% -52.6% -134.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $233.92M $156.49M $103.15M
Total non-current assets * $6.52M $7.93M $5.27M
Total assets $240.44M $164.42M $108.42M
Total current liabilities $69.48M $92.26M $92.06M
Total non-current liabilities * $307.16M $258.17M $309.28M
Total equity -$136.21M -$186.02M -$292.93M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$92.72M -$127.49M -$75.37M
Cash from investing $7.94M $95.47M $43.38M
Cash from financing $1.12M $41.65M $30.05M
Net change in cash -$83.69M $9.62M -$1.92M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.